KRAS and infection: Among patients with HCV GT2a infection who experienced VF in studies M12‐536 or GIFT‐II, treatment‐emergent NS3 substitutions at amino acid position D168 remained detectable in 71.4% (5/7) of patients and 42.9% (3/7) of patients at post‐treatment week 24 and 48, respectively.